


## Additional file 2: Supplementary table S1 and figures S1-S3

Supplementary table 1: demographics


	Patients (N:2081)	Controls (N:178)
<b>Age, mean (SD)</b>	50 (14)	48 (11)
<b>Female sex, N (%)</b>	1306 (62.8)	117 (65.7)
<b>Vaccine type first and second vaccination, N (%):</b>		
CX-024414 (Moderna)	612 (29.4)	105 (60.3)
BNT162b2 (Pfizer/BioNtech)	1209 (58.1)	65 (37.4)
mRNA vaccine, not further specified	27 (1.3)	2 (1.2)
ChAdOx1 nCoV-19 (AstraZeneca)	233 (11.2)	2 (1.2)
Missing	0 (0)	4 (2.2)
<b>Vaccine type third vaccination, N (%):</b>		
CX-024414 (Moderna)	611 (44.2)	42 (43.3)
BNT162b2 (Pfizer/BioNtech)	478 (34.6)	40 (41.2)
mRNA vaccine, not further specified	292 (21.1)	15 (15.5)
<b>COVID-19 infection prior to vaccination, N (%)</b>	173 (8.3)	43 (24.2)
<b>Immune-mediated inflammatory disorders, N (%):</b>		
<b>Dermatological</b>		
atopic dermatitis	115 (5.5)	
other dermatologic conditions <sup>a</sup>	177 (8.5)	
<b>Neurological</b>		
multiple sclerosis and neuromyelitis optica <sup>b</sup>	343 (16.5)	
myasthenia gravis	123 (5.9)	
inflammatory neuropathies and myopathies <sup>c</sup>	153 (7.4)	
<b>Rheumatological</b>		
rheumatoid arthritis	266 (12.8)	
spondyloarthritis	114 (5.5)	

SLE, and Sjogren's disease	158 (7.6)
vasculitis <sup>d</sup>	72 (3.5)
other rheumatological diseases	28 (1.3)
<b>Gastro-enterological</b>	
Crohn's disease	302 (14.5)
ulcerative colitis	178 (8.6)
other gastro-enterological conditions <sup>e</sup>	46 (2.2)
<b>Other immune-mediated inflammatory disorder</b>	<b>6 (0.3)</b>

a: including vitiligo, pemphigus, psoriasis; b: 5 patients with neuromyelitis optica; c: including chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, myositis; d: including giant-cell arteritis, small vessel vasculitis and other forms of vasculitis; e: including autoimmune hepatitis and autoimmune sclerosing cholangitis.




Supplementary figure 1: study flowchart



*Supplementary figure 2: Adverse events in patients with IMiDs after SARS-CoV-2 vaccination*

Figure showing proportions of the highest reported severity grade by individuals for any of systemic AEs separately for patients (A) and controls (B), first, second and third vaccinations and individuals with or without a preceding SARS-CoV-2 infection during the first 7 days after vaccination. Severity grade 0 indicates no AE, grade 1 indicates no interference in daily life, grade “1 relevant” indicates a grade 1 category lasting more than 2 days, grade 2 indicates some hindrance at daily activities, and grade 3 indicates such hindrance that daily activities could not be performed.



*Supplementary figure 3: Adverse events after SARS-CoV-2 vaccination per IMID*

Figure showing proportions of the highest reported severity grade by individuals for any of systemic adverse events for three largest disease groups and other disorders, separately for first, second and third vaccinations. Severity grade 0 indicates no AE, grade 1 indicates no interference in daily life, grade “1 relevant” indicates a grade 1 category lasting more than 2 days, grade 2 indicates some hindrance at daily activities, and grade 3 indicates such hindrance that daily activities could not be performed.